

chain nodes :
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 16 17 18 21 22 23 24 25 26
chain bonds :
2-41 2-46 3-42 3-45 4-9 8-33 10-32 11-31 12-30 14-43 14-44 17-39 17-40
21-37 22-38 24-34 25-35 26-36
ring bonds :
1-2 1-7 1-14 2-3 3-4 4-5 4-14 5-6 6-7 8-9 8-13 9-10 10-11 11-12 12-13
16-17 16-18 17-18 21-22 21-26 22-23 23-24 24-25 25-26
exact/norm bonds :
1-2 1-7 1-14 4-5 4-14 5-6 6-7 12-30
exact bonds :
2-3 2-41 2-46 3-4 3-42 3-45 4-9 8-33 10-32 11-31 14-43 14-44 16-17
16-18 17-18 17-39 17-40 21-37 22-38 24-34 25-35 26-36
normalized bonds :
8-9 8-13 9-10 10-11 11-12 12-13 21-22 21-26 22-23 23-24 24-25 25-26
isolated ring systems :
containing 1 : 8 : 16 : 21 :

G1:X,[*1],[*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 16:Atom 17:Atom 18:Atom 21:Atom 22:Atom
23:Atom 24:Atom 25:Atom 26:Atom 30:CLASS 31:CLASS 32:CLASS 33:CLASS
34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS
42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 X,[@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 12:35:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 70 TO ITERATE

100.0% PROCESSED 70 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

L2 10 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 12:36:10 ON 10 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 9 Feb 2006 (20060209/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3 1 L2

=> d bib abs

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:534333 CAPLUS
DN 139:101039
TI Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, their preparation, and their application in therapy as nicotinic receptor ligands for treatment of CNS disorders
IN Galli, Frederic; Leclerc, Odile; Lochead, Alistair
PA Sanofi-Synthelabo, Fr.
SO Fr. Demande, 20 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2834511	A1	20030711	FR 2002-109	20020107
	FR 2834511	B1	20040213		
	CA 2471628	AA	20030717	CA 2003-2471628	20030103
	WO 2003057697	A1	20030717	WO 2003-FR4	20030103
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003216777	A1	20030724	AU 2003-216777	20030103
	EP 1465893	A1	20041013	EP 2003-712202	20030103
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003006707	A	20050209	BR 2003-6707	20030103
	JP 2005514422	T2	20050519	JP 2003-558012	20030103
	US 2005020568	A1	20050127	US 2004-500015	20040623
	NO 2004002846	A	20040921	NO 2004-2846	20040705
PRAI	FR 2002-109	A	20020107		
	WO 2003-FR4	W	20030103		

OS MARPAT 139:101039
GI

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II



III

AB Title compds. I and their acid addition salts are disclosed [wherein: R = halo, a Ph group (substituted by one or more groups chosen from halo, C1-6 alkyl or alkoxy, NO2, amino, CF3, cyano, OH, acetyl, or methylenedioxy), pyridinyl, thienyl, indolyl, or pyrimidinyl (possibly substituted by one or more C1-6 alkoxy); dashed bonds = one single bond and another single or double bond]. The compds. are useful as pharmaceuticals, particularly as CNS agents, and specifically as ligands of nicotinic receptors. The compds. were tested against nicotinic receptors with the α4β2 subunit, or with the α7 subunit. Four synthetic examples and a list of 35 specific compds. (as either di- or tri-HBr or 1:1 oxalate salts) are given. For instance, 2,5-dibromopyridine was arylated in the 2-position by PhB(OH)2 using Pd(PPh3)4 catalyst, and the resultant 5-bromo-2-phenylpyridine was lithiated with BuLi and treated with 1-azabicyclo[2.2.2]octan-3-one to give the bicyclic alc. II. Dehydration and rearrangement of II by heating with MeSO3H at 180° gave invention compound III, isolated as the di-HBr salt. In tests for specific binding to isolated rat cerebral nicotinic receptors having either α4β2 or α7 subunits, compds. I had IC50 values in the ranges of 0.01-10 μM and 0.005-20 μM, resp. Some compds. showed selectivity for the α7 receptor subtype.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT